Shin Nippon Biomedical Laboratories Ltd. (2395) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Shin Nippon Biomedical Laboratories Ltd. (2395:JPX), powered by AI.

Current Price
¥1,079
P/E Ratio
9.1
Market Cap
44.9B
Sector
Healthcare
What is the Shin Nippon Biomedical Laboratories Ltd. stock price forecast?

Shin Nippon Biomedical Laboratories Ltd. is currently trading at ¥1,079. View real-time AI analysis on Alpha Lenz.

What is Shin Nippon Biomedical Laboratories Ltd. insider trading activity?

View the latest insider trading data for Shin Nippon Biomedical Laboratories Ltd. on Alpha Lenz.

What is Shin Nippon Biomedical Laboratories Ltd.'s P/E ratio?

Shin Nippon Biomedical Laboratories Ltd.'s P/E ratio is 9.1.

Shin Nippon Biomedical Laboratories Ltd.

JPX · 2395
¥1,079-6(-0.55%)Market closedJPX regular session 09:00–15:00 JST
Ask about Shin Nippon Biomedical Laboratories Ltd.'s future dividend policy...
Alpha Chat Insight

Shin Nippon Biomedical Laboratories Ltd. trades at a P/E of 9.1 (undervalued) with solid ROE of 13.3%. 3Y revenue CAGR of 22.2% highlights clear growth momentum.

Ask for details

Company Overview

Shin Nippon Biomedical Laboratories Ltd. is a leading provider in the field of preclinical and clinical research services. The company primarily focuses on delivering comprehensive and high-quality research solutions to the pharmaceutical, biotechnology, and medical device sectors. Known for its advanced technological capabilities and scientific expertise, Shin Nippon Biomedical Laboratories plays a critical role in the drug development and medical research processes, offering services such as toxicology studies, pharmacokinetics, and bioanalysis. Its operations are pivotal in ensuring the safety and efficacy of new therapeutic compounds before they proceed to market. Based in Japan, the firm has established a robust presence in the global research landscape, underpinned by its adherence to rigorous regulatory standards and commitment to innovative research methodologies. Its contributions are vital in expediting the development of new medical treatments and enhancing the overall efficiency of the healthcare and life sciences industries.

CEODr. Ryoichi Nagata F.F.P.M., M.D., Ph.D.
SectorHealthcare
IndustryDiagnostics & Research
Employees1,541

Company Statistics

FY 2025

Profile

¥44,922,740,720Market Cap
¥32,413,807,000Revenue
0.00Shares Out
1,541Employees

Margins

52.33%Gross
28.64%EBITDA
9.21%Operating
18.55%Pre-Tax
15.01%Net

Valuation

9.12P/E
1.12P/B
1.39EV/Sales
7.26EV/EBITDA
-11.53P/FCF

Growth (CAGR)

22.23%Rev 3Yr
17.36%Rev 5Yr
-10.73%Op Inc 3Yr
6.02%Op Inc 5Yr
-12.12%Net Inc 3Yr
12.93%Net Inc 5Yr

Returns

5.77%ROA
13.29%ROE
7.37%ROIC

Financial Health

¥12,032,136,000Cash & Cash Equivalents
¥40,298,784,000Net Debt
130.55%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Shin Nippon Biomedical Laboratories Ltd. (ticker: 2395) is a company listed on JPX in the Healthcare sector (Diagnostics & Research). It has approximately 1,541 employees. Market cap is $44.9B.

The current price is 1,079 with a P/E ratio of 9.12x and P/B of 1.12x.

ROE is 13.29% and operating margin is 9.21%. Annual revenue is $32.4B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Shin Nippon Biomedical Laboratories Ltd. (2395) Stock Forecast 2026 ¥1,079 — Price, Financials & Analyst Targets | Alpha Lenz